STOCK TITAN

Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Monogram Technologies (NASDAQ:MGRM) provided an update following its Submission Issue Request (SIR) meeting with the FDA regarding its 510(k) premarket filing for the mBôs TKA System. The company's July 2024 application received an Additional Information Request (AIR) on September 30, putting the application on hold. Following the December 17 SIR meeting, management believes its comprehensive plans will satisfy the FDA without requiring clinical data.

The company anticipates providing a complete AIR response in Q1 2025. Key upcoming milestones include seeking regulatory clearance for clinical trials in India with Shalby Hospitals, shipping a robot to India for trial training by January 2025, and pursuing FDA clearance for the mBôs TKA System while expanding domestic and international relationships.

Monogram Technologies (NASDAQ:MGRM) ha fornito un aggiornamento dopo il suo incontro per la Richiesta di Problema di Invio (SIR) con la FDA riguardo alla sua domanda di premercato 510(k) per il sistema mBôs TKA. La domanda dell'azienda, presentata a luglio 2024, ha ricevuto una Richiesta di Informazioni Aggiuntive (AIR) il 30 settembre, mettendo l'applicazione in sospeso. A seguito dell'incontro SIR del 17 dicembre, la direzione ritiene che i suoi piani complessivi soddisferanno la FDA senza richiedere dati clinici.

L'azienda prevede di fornire una risposta completa all'AIR nel primo trimestre del 2025. Tra le prossime scadenze chiave ci sono la ricerca di autorizzazioni regolatorie per studi clinici in India con gli Ospedali Shalby, la spedizione di un robot in India per la formazione dei trial entro gennaio 2025 e la richiesta di autorizzazione FDA per il sistema mBôs TKA, espandendo al contempo le relazioni nazionali e internazionali.

Monogram Technologies (NASDAQ:MGRM) proporcionó una actualización después de su reunión de Solicitud de Problema de Presentación (SIR) con la FDA con respecto a su presentación previa al mercado 510(k) para el sistema mBôs TKA. La solicitud de la empresa, enviada en julio de 2024, recibió una Solicitud de Información Adicional (AIR) el 30 de septiembre, poniendo la solicitud en espera. Tras la reunión SIR del 17 de diciembre, la dirección cree que sus planes globales satisfarán a la FDA sin necesidad de datos clínicos.

La empresa anticipa proporcionar una respuesta completa a la AIR en el primer trimestre de 2025. Los próximos hitos clave incluyen buscar la aprobación regulatoria para ensayos clínicos en India con los Hospitales Shalby, enviar un robot a India para entrenamiento de ensayos antes de enero de 2025 y buscar la autorización de la FDA para el sistema mBôs TKA, mientras expande las relaciones nacionales e internacionales.

모노그램 테크놀로지스 (NASDAQ:MGRM)는 mBôs TKA 시스템에 대한 510(k) 사전 시장 제출과 관련하여 FDA와의 제출 문제 요청(SIR) 회의 후 업데이트를 제공했습니다. 회사의 2024년 7월 신청은 9월 30일에 추가 정보 요청(AIR)을 받았으며, 이로 인해 신청이 보류되었습니다. 12월 17일 SIR 회의 후 경영진은 자사의 종합 계획이 FDA의 요구를 충족할 것이라고 믿고 있으며, 임상 데이터는 필요하지 않을 것이라고 합니다.

회사는 2025년 1분기에 AIR에 대한 완전한 응답을 제공할 것으로 예상하고 있습니다. 주요 예정된 이정표로는 Shalby 병원과 함께 인도에서의 임상 시험을 위한 규제 승인을 요청하고, 2025년 1월 이전에 시험 교육을 위한 로봇을 인도로 배송하며, mBôs TKA 시스템에 대한 FDA 승인을 추구하고 국내 및 국제 관계를 확장하는 것이 포함됩니다.

Monogram Technologies (NASDAQ:MGRM) a fourni une mise à jour suite à sa réunion de Demande de Problème de Soumission (SIR) avec la FDA concernant son dépôt 510(k) pré-commercial pour le système mBôs TKA. La demande de l'entreprise, soumise en juillet 2024, a reçu le 30 septembre une Demande d'Informations Supplémentaires (AIR), mettant la demande en attente. Suite à la réunion SIR du 17 décembre, la direction estime que ses plans globaux satisferont la FDA sans nécessiter de données cliniques.

L'entreprise prévoit de fournir une réponse complète à l'AIR au premier trimestre 2025. Les prochaines étapes clés incluent la recherche d'une autorisation réglementaire pour des essais cliniques en Inde avec les Hôpitaux Shalby, l'expédition d'un robot en Inde pour la formation à l'essai d'ici janvier 2025, et la poursuite de l'approbation de la FDA pour le système mBôs TKA tout en élargissant les relations nationales et internationales.

Monogram Technologies (NASDAQ:MGRM) hat ein Update nach seinem Submission Issue Request (SIR) Treffen mit der FDA in Bezug auf seinen 510(k) Antrag für das mBôs TKA System bereitgestellt. Der Antrag des Unternehmens vom Juli 2024 erhielt am 30. September eine Anfrage nach zusätzlichen Informationen (AIR), wodurch der Antrag ausgesetzt wurde. Nach dem SIR-Treffen am 17. Dezember ist die Unternehmensführung der Meinung, dass ihre umfassenden Pläne die Anforderungen der FDA ohne klinische Daten erfüllen werden.

Das Unternehmen plant, eine vollständige Antwort auf die AIR im ersten Quartal 2025 vorzulegen. Wichtige bevorstehende Meilensteine umfassen die Beantragung regulatorischer Genehmigungen für klinische Studien in Indien mit den Shalby-Krankenhäusern, den Versand eines Roboters nach Indien zur Schulung der Studien bis Januar 2025 und die Verfolgung der FDA-Genehmigung für das mBôs TKA System sowie die Erweiterung nationaler und internationaler Beziehungen.

Positive
  • Management anticipates FDA concerns can be addressed without clinical data requirement
  • Company passed initial FDA Administrative Review
  • Strategic partnership with Shalby Hospitals for clinical trials in India
  • Planned expansion of domestic and international relationships
Negative
  • FDA placed 510(k) application on hold pending AIR response
  • 180-day deadline from September 30 to respond to AIR
  • Clearance timeline extended to at least Q1 2025

Insights

The FDA meeting outcome represents a positive development for Monogram's 510(k) submission for their mBôs TKA System. The absence of clinical data requirements significantly streamlines the approval process, potentially reducing both time and costs. The FDA's acceptance of non-clinical testing as sufficient validation is particularly noteworthy for a robotic surgical system. The company's proactive approach in addressing the Additional Information Request (AIR) and their clear timeline for comprehensive response in Q1 2025 demonstrates strong regulatory strategy. The parallel pursuit of clinical trials in India while seeking FDA clearance shows a well-structured global market entry strategy. The regulatory pathway appears manageable with no major red flags raised during the SIR meeting.

The mBôs TKA System's regulatory progress positions Monogram strategically in the growing robotic orthopedic surgery market. The multi-generational product strategy suggests a long-term vision for platform development. The planned expansion into India through Shalby Hospitals partnership provides valuable international market exposure and real-world clinical experience. The absence of clinical data requirements for FDA submission significantly reduces the regulatory burden compared to competitors. The company's presence at Arab Health and pursuit of domestic relationships indicates a comprehensive commercialization strategy. The development of next-generation systems while pursuing current approval demonstrates strong R&D pipeline management.

Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Request

Management Anticipates a Comprehensive AIR Response in Q1 2025

AUSTIN, TEXAS / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application").

The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. On September 30, 2024, Monogram received an Additional Information Request ("AIR") from the FDA. The FDA informed the Company that the FDA placed the Application on hold pending a complete response to the AIR. The FDA informed the Company that the Company had 180 days from the date of the AIR to provide a complete response to the AIR, or the FDA would consider the Application withdrawn.

On November 20, the Company submitted written responses, including planned remediations where applicable for all deficiencies noted in the AIR, and requested a Submission Issue Request (SIR) meeting with the FDA to review select responses. A critical focus for the Company has been whether the proposed nonclinical testing effectively mitigates FDA concerns that could necessitate clinical data. On December 11, 2024, the Company received a Submission Issue Request (SIR) review letter that provided preliminary written comments on particular topics of interest before the SIR meeting scheduled for December 17, 2024. On December 17, 2024, the Company conducted a Submission Issue Request (SIR) meeting with the FDA.

Management believes its comprehensive plans to address the Additional Information Request (AIR) could effectively satisfy the agency and anticipates that in light of its proposed testing, it will be unlikely that the FDA will request clinical data as part of its submission. The Company is actively executing the additional testing and anticipates that it will provide a comprehensive AIR response in the first quarter of 2025. Obtaining clearance would be a significant milestone for its mission to advance the standard of care in orthopedic medicine. The Company is already working on the next-generation version of the mBôs TKA System.

"This meeting reaffirmed our strategic decision to effectuate a multigenerational product strategy and submit the mBôs TKA System for FDA clearance on an accelerated timeline," said Ben Sexson, CEO of Monogram Technologies. "This meeting resolved outstanding questions and was a significant step forward in our path toward commercialization of the mBôs TKA System and execution of our long-term road map. The feedback and guidance provided by the FDA during the Submission Issue Request meeting validate the robustness of our approach. Importantly, the absence of a requirement for clinical data further underscores the confidence we have in the strength of our submission. The Agency's comments provided valuable clarity and affirmed that the proposed testing plans are well aligned with their expectations. We are optimistic that the additional data we are generating will comprehensively address the outstanding items and further reinforce our submission. We remain committed to achieving FDA clearance as quickly as possible, driven by our mission to advance the standard of care in orthopedic medicine."

Upcoming Milestones

  • The Company anticipates it will respond to the FDA AIR with supplemental data in Q1 2025.

  • The Company is seeking to obtain regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals.

  • The Company anticipates shipping a robot to India to initiate clinical trial training by January 2025.

  • The Company is seeking to obtain FDA clearance for the mBôs™ TKA System.

  • Continue exploring domestic relationships.

  • Seek to continue expanding international relationships (the Company will be exhibiting at Arab Health in January 2025).

About Monogram Technologies Inc.

Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.

Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.

Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.

The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.

To learn more, visit www.monogramtechnologies.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. For example, the Company's statement regarding the Company's proposed use of net proceeds is a forward-looking statement. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Investor Relations

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
MGRM@mzgroup.us

SOURCE: Monogram Technologies Inc.



View the original press release on accesswire.com

FAQ

When will Monogram Technologies (MGRM) submit its complete FDA AIR response?

Monogram Technologies anticipates submitting its comprehensive AIR response in Q1 2025.

What is the current status of MGRM's 510(k) application for the mBôs TKA System?

The application is currently on hold pending a complete response to the FDA's Additional Information Request (AIR) received on September 30, 2024.

When did MGRM have its SIR meeting with the FDA regarding the mBôs TKA System?

The SIR meeting with the FDA took place on December 17, 2024.

Will MGRM need to provide clinical data for its mBôs TKA System FDA submission?

Management believes its comprehensive plans will satisfy the FDA without requiring clinical data.

What are MGRM's international expansion plans for the mBôs TKA System?

MGRM is seeking regulatory clearance for clinical trials in India with Shalby Hospitals and plans to exhibit at Arab Health in January 2025.

Monogram Orthopaedics Inc

NASDAQ:MGRM

MGRM Rankings

MGRM Latest News

MGRM Stock Data

76.52M
22.28M
34.22%
3.85%
0.81%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BROOKLYN